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Summary
Objective: To describe the safe substitution with zidovudine (AZT) among South Indian HIV-
infected patients who were initiated with stavudine (d4T)-containing highly active antiretroviral
therapy (HAART) due to anemia.
Methods: Therapy-naı¨ve patients initiating HAART between January 2006 and December 2007 and
who had had d4T substituted for AZT at a tertiary HIV referral center in India were analyzed.
Results: Six hundred and nineteen patients initiated d4T-containing HAART (median CD4 110 cells/
ml; median hemoglobin 10.4 g/dl) during the study period. Subsequently half of these patients
substituted d4T for AZT (median CD4 350 cells/ml; median hemoglobin 12.8 g/dl). After sub-
stituting with AZT, three patients (2.7%) who substituted after less than 6 months and one patient
(0.6%) who substituted at between 6 and 12 months developed anemia. Patients who substituted
after less than 6 months had significantly higher median CD4 cell counts at 1-month and 6-months
of follow-up than patients who substituted at between 6 and 12 months (p < 0.05). Few patients
(1.6%) experienced treatment failure; about a tenth of patients developed d4T-related toxicities.
Conclusion: Few patients developed anemia (1.4%) within 6 months of substitution with AZT. In
settings where tenofovir is either expensive or not available and where patients are anemic,
initiatingd4TfollowedbypromptsubstitutionwithAZTcanbeasafeandtolerabletreatmentoption.
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Current United States Department of Health and Human Ser-
vices (DHHS) and World Health Organization (WHO) treatment
guidelines for initiating highly active antiretroviral therapy
(HAART) for HIV-infected patients recommend tenofovir
(TDF)- or zidovudine (AZT)-containing regimens as preferred
first-line treatment options as compared to stavudine (d4T)-
containing regimens.1,2 In resource-limited settingswhereTDF
is currently either not affordable or unavailable and where
manypatients are anemic and therefore cannot be initiatedon
AZT, d4T-containing regimens have been employed as a first-
line treatment option in diverse settings.3,4
Though d4T-containing regimens have routinely been pre-
scribed as first-line therapy due to low cost and ready fixed-
dose availability, d4T can be associated with long-term toxi-
cities, including lipodystrophy, peripheral neuropathy, and
lactic acidosis.3,5 AZT has been associated with increased
hematological toxicities; prior studies have shown that
patients develop anemia within the first few months of
initiating AZT-containing HAART.4,6 The current study was
conducted to assess the safety and tolerability of substitution
with AZT from d4T-containing HAART regimens among HIV-
infected South Indians.
Methods
Setting
This was a retrospective study conducted at YRG Center for
AIDS Research and Education (YRG CARE), Chennai, which is a
large HIV tertiary care center in South India. Since 1996, it
has provided a continuum of care for over 10 000 HIV-infected
individuals.7 All patients are treated according to the WHO
treatment guidelines. Co-trimoxazole prophylaxis is initiated
for all patients as per WHO guidelines.8 Patients are advised
to initiate antiretroviral therapy (ART) when CD4 counts are
<200 cells/ml or when CD4 counts range between 200 and 350
cells/ml with an AIDS-defining illness (ADI). Nevirapine (NVP)-
based regimens, which are the least expensive and most
widely available, are generally used as first-line therapies.
Patients are seen every 3 months or as clinically indicated.
CD4 monitoring is done every 3 to 6 months.
Patients
Patients who were older than 18 years of age, attending the
YRG CARE clinic between January 2006 and December 2007,
and who had been substituted with AZT from d4T-containing
ARTwere included in this retrospective analysis. Since 2006,
in order to balance the short-term risks posed by AZT therapy
with the long-term toxicities associated with d4T, patients
with hemoglobin <11 g/dl have been initiated on d4T-con-
taining HAART for a minimum of 3—6 months and then sub-
stituted to AZT-containing HAART. Patients were substituted
with AZT after elevation of hemoglobin to >11 g/dl and
underwent evaluation of hemoglobin and hematocrit on
follow-up at 1 month after substitution and then subse-
quently every 3 months. Data were collected with the
approval of YRG CARE’s freestanding institutional review
board (IRB). Analyses used the YRG CARE HIV Natural HistoryStudy Observational Database. This database is updated daily
by research nurses who are trained to use a validated pro-
spective data collection instrument, which includes demo-
graphics, clinical assessments, current treatment regimens
and adverse events (AEs), as well as laboratory data, includ-
ing hemoglobin, liver and renal function tests, CD4 cell
counts, plasma viral load (PVL), and genotypic testing, if
available.
The most recent National Institutes of Health (NIH) defini-
tions of AIDS-associated AEs were employed for diagnosis.9
Treatment failure was used to refer to those patients who
modified therapy because of clinical, immunological, or
virological treatment failure. The clinical criterion for failure
was the development of an AIDS-defining illness after at least
3 months on HAART. According to WHO treatment guidelines,
immunologic failure was defined as a decrease in CD4 to
baseline (or below) after 6 months of therapy, a persistent
CD4 below 100 cells/ml after 6 months of therapy, or a 50%
decline from the on-treatment peak CD4 value.1 Virologic
failure was defined as a viral load>400 copies/ml at 6months
after initiating ART.
Statistical analysis
Descriptive statistics were calculated with means and
standard deviations for variables that were normally dis-
tributed; the median and interquartile range (IQR) were
calculated for variables influenced by extreme values. To
compare proportions, Chi-square statistics were used, and
the Mann—Whitney U-test was used to compare median
durations. All statistical analyses were performed using
SPSS software (version 14.0; SPSS, Chicago, IL, USA). A
p-value of less than 0.05 was considered statistically
significant.
Results
Between January 2006 and December 2007, 619 patients
initiated d4T-containing HAART. Almost half of the patients
(49.8%) initiating d4T subsequently substituted with AZT.
Among these 619 patients, 292 substituted with AZT within
12 months of initiating d4T-containing HAART and had 12
months of follow-up on HAART. Over a third of these patients
(38.4%) substituted within 6 months and 180 patients (61.6%)
substituted at 6—12 months. The following analyses were
undertaken only among these 292 patients who substituted
within 12 months and who also had 12 months of follow-up on
HAART (Table 1; Figure 1).
Close to a third of patients (27.3%) were female and the
median age was 35 years. The median body mass index (BMI)
was 18.9. The two first-line HAART regimens were lamivu-
dine (3TC) plus d4T plus NVP (31%) and 3TC plus d4T plus
efavirenz (EFV) (69%). At the time of initiating HAART, the
median CD4 cell count was 110 cells/ml (IQR 57—187) and
the median hemoglobin was 10.4 g/dl (IQR 9.0—12.1). Few
patients (1.6%) experienced treatment failure and the
median time to treatment failure was 12 months (IQR
0.8—26). Close to a tenth of patients (9.1%) developed
peripheral neuropathy and 4.9% of patients developed
lipoatrophy after initiating d4T-containing HAART. The
median time to development of d4T-related toxicities
was 7 months (IQR 5.8—11.3).
Table 1 Characteristics of patients who substituted with AZT from d4T-containing HAART prior to treatment substitution (N = 292)
Median (IQR), mean (%)
Median CD4 (cells/ml) 110 (57—187)
Median hemoglobin (g/dl) 10.4 (9.0—12.1)
Patients who experienced immunological failure 10 (1.6%)
Median time to treatment failure 12 months (0.8—26)
Patients who developed d4T-related toxicity 44 (7.1%)
Among patients who substituted with AZT <6 months 17 (2.7%)
Among patients who substituted with AZT 6—12 months 27 (4.4%)
Median time to development of d4T-related toxicity 7 months (5.8—11.3)
Median time to substitution with AZT 4 months
AZT, zidovudine; d4T, stavudine; HAART, highly active antiretroviral therapy; IQR, interquartile range.
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350 cells/ml (IQR 219—438) and the median hemoglobin was
12.8 g/dl (IQR 12.5—14.6). The median time to substitution
was 4 months. After substituting with AZT, three patients
(2.7%) who substituted at <6 months on d4T developed
anemia and one patient (0.6%) who substituted after 6—12
months on d4T developed anemia.
At 1 month following initiation of AZT, patients who sub-
stituted after <6 months on d4T had significantly higher CD4
cell counts than patients who substituted after 6—12 months
on d4T (CD4 cell count 391 cells/ml vs. 346 cells/ml; p = 0.024)
(Figure2).At3months following initiationofAZT,patientswho
substituted after <6 months on d4T had significantly lower
hemoglobin levels than patients who substituted after 6—12
monthsond4T (hemoglobin12.6 g/dl vs. 13.5 g/dl;p<0.001).
At 6 months following initiation of AZT, patients who substi-
tuted after<6months on d4T had significantly higher CD4 cell
counts and lower hemoglobin levels than patients who sub-
stituted after 6—12months on d4T (CD4 cell count 453 cells/ml
vs. 445 cells/ml; hemoglobin 13.0 g/dl vs. 13.5 g/dl; p <
0.001). No differences were found in outcomes between
EFV- vs. NVP-containing regimens; additionally no differences
were found in hemoglobin levels between men and women.Figure 1 Flow chart of study participants.Discussion
In resource-limited settings, the selection of HAARTregimens
has been determined not only by treatment efficacy, but also
by considerations of availability and affordability. The cur-
rent study demonstrated the safe substitution with AZT from
d4T-containing HAART, and only a few cases of anemia (1.4%)
were reported after substitution. The findings of the current
study suggest that in settings where TDF is either expensive
or not available and where many patients have low hemo-
globin levels at the time of initiating therapy, starting d4T
followed by prompt substitution with AZT can be a safe and
tolerable treatment option.
In the current study, patients developed d4T-related
toxicity generally after 6 months of initiating d4T. DueFigure 2 CD4 count and hemoglobin comparison between
patients who substituted with AZT at <6 months after initiating
d4T vs. patients who substituted at 6—12 months. *Signifies a
statistically significant difference (p < 0.05).
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apy, it is advisable that patients be substituted as soon as
hemoglobin levels have stabilized. Patients and healthcare
providers should be adequately trained to recognize the
signs and symptoms of possible d4T toxicity, including
lipoatrophy, lactic acidosis, and peripheral neuropathy,
so that early recognition can lead to prompt treatment
substitution.
Rates of anemia have dramatically decreased since the
introduction of HAART, but anemia has been identified as an
independent risk factor for mortality for patients living with
AIDS.10—12 Hence treatment strategies that minimize the
risk of developing anemia are important for effective
patient management. In resource-limited settings, such
as India, HIV-infected patients often present to clinical
care with co-existing nutritional deficiencies, opportunistic
infections, and other chronic diseases that may precipitate
low hemoglobin levels, which can subsequently be exacer-
bated by the use of AZT.3,13,14 An earlier study at our center
documented that patient gender was not associated with
anemia.15
Data on anemia from industrialized nations have used
cutoffs ranging from <8 g/dl to <14 g/dl and have documen-
ted prevalence ranging from 1.3% to 95% in HIV-infected
populations.16 In an earlier study at YRG CARE, 6% of patients
experienced anemia after initiating generic HAART.5 How-
ever, a fifth of the cohort had received AZT, and more than
half of the patients who developed anemia within 1 year of
initiating HAART were on an AZT-containing therapy. In the
present study, which aimed tominimize the risk of developing
anemia through treatment substitution after hemoglobin
stabilization, only 1.4% of patients developed anemia. Other
studies have similarly noted that prior ART experience can
protect against AZT-related anemia.4
The purpose of this study was to focus on this specific
treatment strategy of initiating patients with low hemoglo-
bin on d4T and then substituting this for AZT once hemo-
globin levels improve. A prior study at our center
documented immunological and clinical outcomes of
patients who remained on d4Tand of patients who initiated
AZT as well as rates of anemia among patients on these
treatment regimens.5
Due to the present limitation of available first-line regi-
mens in resource-limited settings, innovative treatment stra-
tegies that can maximize the current formulary andminimize
the risk of drug toxicities for HIV-infected patients are
imperative. The findings of the present study suggest that
once patients are substituted with AZT, regular hemoglobin
monitoring is crucial to detect the short-term risk of anemia.
In light of the increasing number of patients receiving HAART
in resource-limited settings, future studies are needed to
determine the long-term safety and efficacy of such ART
substitution strategies.
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